Gyros AB and Protein Technologies Merge to Form Gyros Protein Technologies AB
The merger creates a provider of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and manufacturing.
The merger creates a provider of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and manufacturing.
Gyros AB and Protein Technologies announced on March 16, 2016 that the companies have entered into a definitive merger agreement to form Gyros Protein Technologies AB. The merger is expected to be complete by mid-April 2016 and is subject to certain closing conditions.
Gyros Protein Technologies combines Gyros’ microfluidics, systems development, and immunoassay knowledge with Protein Technologies’ insight in developing and manufacturing instruments for peptide synthesis. The new company will provide a range of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and bioprocessing. According to a press announcement from the company, Gyros Protein Technologies will be led by Dan Calvo as CEO (currently CEO of Gyros AB) and Erik Wiberg as CFO (currently CFO of Protein Technologies).
Source: Gyros AB
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
